Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number

Cancer Research

Volumn 66, Issue 12, 2006, Pages 6050-6062

  Wang, Qun ^a   Diskin, Sharon ^a,c   Rappaport, Eric ^a   Attiyeh, Edward ^a   Mosse, Yael ^a   Shue, Daniel ^a   Seiser, Eric ^a   Jagannathan, Jayanti ^a   Shusterman, Suzanne ^d,e   Bansal, Manisha ^a   Khazi, Deepa ^a   Winter, Cynthia ^a   Okawa, Erin ^a   Grant, Gregory ^c   Cnaan, Avital ^a   Zhao, Huaqing ^a   Cheung, Nai Kong ^f   Gerald, William ^f   London, Wendy ^g   Matthay, Katherine K ^h   Brodeur, Garrett M ^a   Maris, John M ^a,b   more..

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g Children's Oncology Group ^*  (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA;

ADOLESCENT; ADULT; AGED; ARTICLE; CELL PROLIFERATION; CHILD; CHROMOSOME DELETION; CONTROLLED STUDY; DNA MICROARRAY; GENE AMPLIFICATION; GENE LOCUS; GENE MAPPING; GENE TARGETING; GENOMICS; HUMAN; HUMAN TISSUE; INFANT; MAJOR CLINICAL STUDY; MUTATION; NERVE CELL DIFFERENTIATION; NEUROBLASTOMA; NEWBORN; PHYLOGENETIC TREE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS;

CHROMOSOME ABERRATIONS; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TARGETING; GENOME, HUMAN; GENOMICS; HUMANS; INFANT; LOSS OF HETEROZYGOSITY; NEUROBLASTOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 33745700217     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-4618     Document Type: Article

References (79)

1. Brodeur GM, Maris JM. Neuroblastoma. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. 4th ed. Philadelphia: J.B. Lippincott Co.; 2002. p.895-938.
2. Maris JM. The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr Opin Pediatr 2005;17:7-13.
3. Breslow N, McCann B. Statistical estimation of prognosis for children with neuroblastoma. Cancer Res 1971;31:2098-103.
4. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-77.
5. Shimada H, Ambros IM, Dehner LP, et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999;86:364-72.
6. Look AT, Hayes FA, Shuster JJ, Douglass EC, Castleberry RP, Brodeur GM. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 1991;9:581-91.
7. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121-4.
8. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313:1111-6.
9. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-16.
10. Schmidt ML, Lukens JN, Seeger RC, et al. Biologic factors determine prognosis in infants with stage FV neuroblastoma: a prospective Children's Cancer Group study. J Clin Oncol 2000;18:1260-8.
11. Cohn SL, Tweddle DA. MYCN amplification remains prognostically strong 20 years after its "clinical debut." Eur J Cancer 2004;40:2639-42.
12. Mans JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol 1999;17:2264-79.
13. Attiyeh EF, London WB, Mosse YP, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005;353:2243-53.
14. Nigro JM, Misra A, Zhang L, et al. Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res 2005;65:1678-86.
15. Yi Y, Mirosevich J, Shyr Y, Matusik R, George AL, Jr. Coupled analysis of gene expression and chromosomal location. Genomics 2005;85:401-12.
16. Alaminos M, Mora J, Cheung NK, et al. Genome-wide analysis of gene expression associated with MYCN in human neuroblastoma. Cancer Res 2003;63:4538-46.
17. Wei JS, Greer BT, Westermann F, et al. Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res 2004;64:6883-91.
18. Ohira M, Oba S, Nakamura Y, Hirata T, Ishii S, Nakagawara A. A review of DNA microarray analysis of human neuroblastomas. Cancer Lett 2005;228:5-11.
19. McArdle L, McDermott M, Purcell R, et al. Oligonucleotide microarray analysis of gene expression in neuroblastoma displaying loss of chromosome 11q. Carcinogenesis 2004;25:1599-609.
20. Mathew P, Valentine MB, Bowman LC, et al. Detection of MYCN gene amplification in neuroblastoma by fluorescence in situ hybridization: a pediatric oncology group study. Neoplasia 2001;3:105-9.
21. Morowitz M, Shusterman S, Mosse Y, et al. Detection of single-copy chromosome 17q gain in human neuro-blastomas using real-time quantitative polymerase chain reaction. Mod Pathol 2003;16:1248-56.
22. Alaminos M, Gerald WL, Cheung NK. Prognostic value of MYCN and ID2 overexpression in neuroblastoma. Pediatr Blood Cancer 2005;45:909-15.
23. Ashburner M, Ball CA, Blake JA, et al. Gene Ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000;25:25-9.
24. Hosack DA, Dennis G, Jr., Sherman BT, Lane HC, Lempicki RA. Identifying biological themes within lists of genes with EASE. Genome Biol 2003;4:R70.
25. Manduchi E, Grant GR, McKenzie SE, Overton GC, Surrey S, Stoeckert CJ, Jr. Generation of patterns from gene expression data by assigning confidence to differentially expressed genes. Bioinformatics 2000;16:685-98.
26. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21.
27. Kent WJ, Sugnet CW, Furey TS, et al. The human genome browser at UCSC. Genome Res 2002;12:996-1006.
28. Wang Q, Hu G, Shusterman S, et al. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas. Cancer Res 2003;63:1631-5.
29. Vandesompele J, Baudis M, De Preter K, et al. Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J Clin Oncol 2005;23:2280-99.
30. Shohet JM, Hicks MJ, Pion SE, et al. Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma. Cancer Res 2002;62:1123-8.
31. Breen CJ, O'Meara A, McDermott M, Mullarkey M, Stalling RL. Coordinate deletion of chromosome 3p and 11q in neuroblastoma detected by comparative genomic hybridization. Cancer Genet Cytogenet 2000;120:44-9.
32. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;286:531-7.
33. Khan J, Wei JS, Ringner M, et al. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med 2001;7:673-9.
34. Yang XJ, Tan MH, Kim HL, et al. A molecular classification of papillary renal cell carcinoma. Cancer Res 2005;65:5628-37.
35. Haven CJ, Howell VM, Eilers PH, et al. Gene expression of parathyroid tumors: molecular subclassification and identification of the potential malignant phenotype. Cancer Res 2004;64:7405-11.
36. Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 2004;64:7205-9.
37. Reiter JL, Brodeur GM. High-resolution mapping of a 130-kb core region of the MYCN amplicon in neuroblastomas. Genomics 1996;32:97-103.
38. Vasudevan SA, Nuchtern JG. Gene profiling of high risk neuroblastoma. World J Surg 2005;29:317-24.
39. Bown N, Cotterill S, Lastowska M, et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 1999;340:1954-61.
40. Chang CL, Zhu XX Thoraval DH, et al. Nm23-1 mutation in neuroblastoma. Nature 1994;370:335-6.
41. Valentijn LJ, Koppen A, van Asperen R, Root HA, Haneveld F, Versteeg R. Inhibition of a new differentiation pathway in neuroblastoma by copy number defects of N-myc, Cdc42, and nm23 genes. Cancer Res 2005;65:3136-45.
42. Saito-Ohara F, Imoto I, Inoue J, et al. PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res 2003;63:1876-83.
43. Maris JM, Weiss MJ, Guo C, et al. Loss of heterozygosity at Ip36 independently predicts for disease progression, but not decreased overall survival probability, in neuroblastoma patients: a Children's Cancer Group study. J Clin Oncol 2000;18:1888-99.
44. Matthay KK, Villabianca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165-73.
45. Cooper R, Khakoo Y, Matthay KK, et al. Opsoclonusmyoclonus-ataxia syndrome in neuroblastoma: histopathologic features-a report from the Children's Cancer Group. Med Pediatr Oncol 2001;36:623-9.
46. Gambini C, Conte M, Bernini G, et al. Neuroblastic tumors associated with opsoclonus-myoclonus syndrome: histological, immunohistochemical and molecular features of 15 Italian cases. Virchows Arch 2003;442:555-62.
47. Shimada H. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer 2001;92:2451-61.
48. Janoueix-Lerosey I, Novikov E, Monteiro M, et al. Gene expression profiling of 1p35-36 genes in neuroblastoma. Oncogene 2004;23:5912-22.
49. Caren H, Ejeskar K, Fransson S, et al. A cluster of genes located in 1p36 are down-regulated in neuroblastomas with poor prognosis, but not due to CpG island methylation. Mol Cancer 2005;4:10.
50. Teitz T, Wei T, Liu D, et al. Caspase-9 and Apaf-1 are expressed and functionally active in human neuroblastoma tumor cell lines with 1p36 LOH and amplified MYCN. Oncogene 2002;21:1848-58.
51. Abel F, Sjoberg RM, Nilsson S, Kogner P, Martinsson T. Imbalance of the mitochondrial pro- and antiapoptotic mediators in neuroblastoma tumours with unfavourable biology. Eur J Cancer 2005;41:635-46.
52. Barbashina V, Salazar P, Holland EC, Hosenblum MK. Ladanyi M. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on Ip36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin Cancer Res 2005;11:1119-28.
53. White PS, Thompson PM, Gotoh T, et al. Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma. Oncogene 2005;24:2684-94.
54. Lahti JM, Valentine M, Xiang J, et al. Alterations in the PITSLRE protein kinase gene complex on chromosome 1p36 in childhood neuroblastoma. Nat Genet 1994;7:370-5.
55. He L, Yu JX Liu L, et al. RIZ1, but not the alternative RIZ2 product of the same gene, is underexpressed in breast cancer, and forced RIZ1 expression causes G2-M cell cycle arrest and/or apoptosis. Cancer Res 1998;58:4238-44.
56. Thompson PM, Gotoh T, Kok M, White PS, Brodeur GM. CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system. Oncogene 2003;22:1002-11.
57. Bilke S, Chen QR, Westerman F, Schwab M, Catchpoole D, Khan J. Inferring a tumor progression model for neuroblastoma from genomic data. J Clin Oncol 2005;23:7322-31.
58. Selzer RR, Richmond TA, Pofahl NJ, et al. Analysis of chromosome breakpoints in neuroblastoma at subkilobase resolution using fine-tiling oligonucleotide array CGH. Genes Chromosomes Cancer 2005;44:305-19.
59. Mosse Y, Greshock J, King A, Khazi D, Weber BL, Maris JM. Identification and high-resolution mapping of a constitutional 11q deletion in an infant with multifocal neuroblastoma. Lancet Oncol 2003;4:769-71.
60. Satge D, Moore SW, Stiller CA, et al. Abnormal constitutional karyotypes in patients with neuroblastoma: a report of four new cases and review of 47 others in the literature. Cancer Genet Cytogenet 2003;147:89-98.
61. Guo C, White PS, Weiss MJ, et al. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene 1999;18:4948-57.
62. De Preter K, Vandesompele J, Menten B, et al. Positional and functional mapping of a neuroblastoma differentiation gene on chromosome 11. BMC Genomics 2005;6:97.
63. Kuramochi M, Fukuhara H, Nobukuni T, et al. TSLC1 is a tumor-suppressor gene in human non-small-cell lung cancer. Nat Genet 2001;27:427-30.
64. Neumann HP, Bausch B, McWhinney SR, et al. Germline mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002;346:1459-66.
65. Milne TA, Hughes CM, Lloyd R, et al. Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc Natl Acad Sci U S A 2005;102:749-54.
66. Wang SS, Esplin ED, Li JL, et al. Alterations of the PPP2R1B gene in human lung and colon cancer. Science 1998;282:284-7.
67. Bartkova J, Horejsi Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005;434:864-70.
68. Blaheta RA, Hundemer M, Mayer G, et al. Expression level of neural cell adhesion molecule (NCAM) inversely correlates with the ability of neuroblastoma cells to adhere to endothelium in vitro. Cell Commun Adhes 2002;9:131-47.
69. Collado M, Gil J, Efeyan A, et al. Tumour biology: senescence in premalignant tumours. Nature 2005;436:642.
70. De Preter K, Vandesompele J, Hoebeeck J, et al. No evidence for involvement of SDHD in neuroblastoma pathogenesis. BMC Cancer 2004;4:55.
71. Teitz T, Wei T, Valentine MB, et al. Caspase 8 is deleted or silenced preferentially in childhood neuro-blastomas with amplification of MYCN. Nat Med 2000;6:529-35.
72. Yang Q, Zage P, Kagan D, et al. Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma. Clin Cancer Res 2004;10:8493-500.
73. Yang QW, Liu S, Tian Y, et al. Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma. Cancer Res 2003;63:6299-310.
74. Misawa A, Inoue J, Sugino Y, et al. Methylation-associated silencing of the nuclear receptor 112 gene in advanced-type neuroblastomas, identified by bacterial artificial chromosome array-based methylated CpG island amplification. Cancer Res 2005;65:10233-42.
75. Banelli B, Gelvi I, Di Vinci A, et al. Distinct CpG methylation profiles characterize different clinical groups of neuroblastic tumors. Oncogene 2005;24:5619-28.
76. Abe M, Ohira M, Kaneda A, et al. CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas. Cancer Res 2005;65:828-34.
77. Mosse YP, Greshock J, Margolin A, et al. High-resolution detection and mapping of genomic DNA alterations in neuroblastoma. Genes Chromosomes Cancer 2005;43:390-403.
78. Manning G, Whyte DB, Martinez R, Hunter T. Sudarsanam S. The protein kinase complement of the human genome. Science 2002;298:1912-34.
79. Reiter JL, Brodeur GM. MYCN is the only highly expressed gene from the core amplified domain in human neuroblastomas. Genes Chromosomes Cancer 1998;23:134-40.